Step aside AstraZeneca, Pfizer/Merck KGaA jump ahead, getting a speedy review for their checkpoint rival avelumab
Now it’s Pfizer’s turn to jump into the hotly contested checkpoint market.
The pharma giant and its partner Merck KGaA say that the FDA has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
